Literature DB >> 11136718

Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis.

C A Johnson1, K Padget, C A Austin, B M Turner.   

Abstract

DNA topoisomerase II (topo II) is a ubiquitous nuclear enzyme that is involved in DNA replication, transcription, chromosome segregation, and apoptosis. Here we show by immunoprecipitation, pull down with glutathione S-transferase fusion proteins, and yeast two-hybrid analysis that both topo IIalpha and -beta physically interact with the histone deacetylase HDAC1. The in vitro DNA decatenation activity of recombinant topo IIalpha and -beta is inhibited by association with catalytically inactive, recombinant HDAC1. We provide evidence for the in vivo significance of the topo II-HDAC1 association, showing that inhibition of HDAC activity with trichostatin A suppresses apoptosis induced by the topo II poison etoposide, but not by the topoisomerase I inhibitor camptothecin. We suggest that chromatin remodeling by an HDAC-containing complex facilitates both topo II-catalyzed DNA rearrangement and etoposide-induced DNA damage in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11136718     DOI: 10.1074/jbc.C000824200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  Aberrant lamination in the cerebral cortex of mouse embryos lacking DNA topoisomerase IIbeta.

Authors:  Yi Lisa Lyu; James C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-28       Impact factor: 11.205

2.  Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.

Authors:  William Guerrant; Vishal Patil; Joshua C Canzoneri; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2012-02-13       Impact factor: 7.446

3.  Combination of HDAC and topoisomerase inhibitors in small cell lung cancer.

Authors:  Jhanelle Gray; Christopher L Cubitt; Shumin Zhang; Alberto Chiappori
Journal:  Cancer Biol Ther       Date:  2012-06-01       Impact factor: 4.742

4.  Decondensing the protamine domain for transcription.

Authors:  Rui Pires Martins; Stephen A Krawetz
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-01       Impact factor: 11.205

Review 5.  DNA topoisomerase II and its growing repertoire of biological functions.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

6.  Topoisomerase IIbeta is required for lamina-specific targeting of retinal ganglion cell axons and dendrites.

Authors:  Linda M Nevin; Tong Xiao; Wendy Staub; Herwig Baier
Journal:  Development       Date:  2011-06       Impact factor: 6.868

7.  p53 Deficiency rescues neuronal apoptosis but not differentiation in DNA polymerase beta-deficient mice.

Authors:  Noriyuki Sugo; Naoko Niimi; Yasuaki Aratani; Keiko Takiguchi-Hayashi; Hideki Koyama
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

8.  Human topoisomerase IIalpha: targeting to subchromosomal sites of activity during interphase and mitosis.

Authors:  Marta Agostinho; José Rino; José Braga; Fernando Ferreira; Soren Steffensen; João Ferreira
Journal:  Mol Biol Cell       Date:  2004-02-20       Impact factor: 4.138

9.  Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

Authors:  P N Munster; D Marchion; S Thomas; M Egorin; S Minton; G Springett; J-H Lee; G Simon; A Chiappori; D Sullivan; A Daud
Journal:  Br J Cancer       Date:  2009-09-08       Impact factor: 7.640

10.  In vitro nuclear interactome of the HIV-1 Tat protein.

Authors:  Virginie W Gautier; Lili Gu; Niaobh O'Donoghue; Stephen Pennington; Noreen Sheehy; William W Hall
Journal:  Retrovirology       Date:  2009-05-19       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.